Azer-Cel and Vaxinia, the bile duct trial, are in a Ph1b. Ph1b...

Azer-Cel and Vaxinia, the bile duct trial, are in a Ph1b. Ph1b is generally speaking a shortened Ph2 version which can be seen as a "fast / accelerated" development when the FDA sees an urgent need and when the pre-clinical as well as Ph1 data are supporting it. Normally those ph1b trials, when meeting the expectations, lead to the shortened rego trials which can be seen as a ph3 equivalent.

That's why IMU is focusing on these 2 plus is hoping / assessing the other MAST-data to have at least another one to get into a ph1b.

That above should warrant a MC in the $$ billions. But as there is no pharma or industry - related investor in sight doubts remain whether the data are really top notch and, even if they get regos for all, will IMU be able to sell them?

Anything that smells like a paradigm shift will find investors, the fact that IMU can't get them on board justifies the doubts and distrust in management.

Let's see what they come up with on Wednesday but everyone be warned here, don't expect anything that could send the sp North, get prepared for the worst. Unless, Hopper announces his resignation......but that won't happen unless he gets forced and as there is no major sh to pressure him.... the odds for that to happen are ZERO.

GLTA